Antibacterial agent 330
Antibacterial agent 330 is an antibacterial agent. Antibacterial agent 330 triggers ROS accumulation, forms DNA supramolecular complex by intercalation to block DNA replication and inhibits LDH to
disturb metabolism, and further prompts bacterial cell rupture to induce the leakage of intracellular content, ultimately causing bacterial death. Antibacterial agent 330 displays antibacterial activity and promotes wound healing in both G. Mellonella larval and murine wound infection models. Antibacterial agent 330 can be used for the research of bacterial infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 3031427-16-1
- 화학식: C34H36ClN4O10PS
- 분자량:759.16
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
제품 설명
disturb metabolism, and further prompts bacterial cell rupture to induce the leakage of intracellular content, ultimately causing bacterial death. Antibacterial agent 330 displays antibacterial activity and promotes wound healing in both G. Mellonella larval and murine wound infection models. Antibacterial agent 330 can be used for the research of bacterial infections[1].
In Vitro
Antibacterial agent 330 (Compound I-10b) potently inhibits the growth of multiple Gram-positive and Gram-negative bacterial strains (MICs =
0.0007-0.0026 mM), with the lowest MIC of 0.0003 mM against Enterococcus faecalis, and also inhibits clinically isolated Enterococcus faecalis strains at low concentrations[1].
Antibacterial agent 330 (4×-8× MIC; up to 8 h) exhibits concentration-dependent bactericidal activity against Staphylococcus aureus 25923 and Enterococcus faecalis, with significant CFU reduction observed at 8× MIC within 6 hours[1].
Antibacterial agent 330 (14 days) shows low potential to induce bacterial resistance in Staphylococcus aureus 25923 and Enterococcus faecalis, and potently inhibits sulfamethoxazole-resistant bacterial strains at low concentrations (0.0007-0.0055 mM)[1].
Antibacterial agent 330 (32×-64× MIC; 4 h) exhibits negligible hemolytic toxicity[1].
Antibacterial agent 330 (5-40 μg/mL) shows no significant cytotoxicity to human normal LO2 hepatic cells and Beas-2b lung epithelial cells[1].
Antibacterial agent 330 (0.5×-16× MIC) effectively inhibits and eradicates biofilms of Staphylococcus aureus 25923 and Enterococcus faecalis in a concentration-dependent manner, with over 40% eradication of Staphylococcus aureus 25923 biofilm at 16× MIC[1].
Antibacterial agent 330 (1×-16× MIC) increases membrane permeability in Staphylococcus aureus 25923 and Enterococcus faecalis[1].
Antibacterial agent 330 (0.5×-8× MIC) induces concentration-dependent protein leakage from Staphylococcus aureus 25923 and Enterococcus faecalis, indicating bacterial membrane damage[1].
Antibacterial agent 330 (0.5×-16× MIC) triggers concentration-dependent intracellular ROS accumulation in Staphylococcus aureus 25923 and Enterococcus faecalis[1].
Antibacterial agent 330 (4×-16× MIC) inhibits LDH activity in Staphylococcus aureus 25923 and Enterococcus faecalis by ~45% at 16× MIC[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Antibacterial agent 330 (4× MIC; topical; once daily; 6 days) effectively promotes wound healing and reduces S. aureus 25923 bacterial load in a murine wound infection model, while supporting normal mouse weight gain[1].
Antibacterial agent 330 (5 mg/kg/day; daily; 3 days) exhibits good in vivo biosafety in Kunming mice, with no histopathological damage observed in major organs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:S. aureus 25923-infected in Galleria mellonella larvae[1]
-
Dosage:0.007 mM (5× MIC); 0.014 mM (10× MIC)
-
Administration:injection; single dose
-
Result:Achieved a 90% survival rate at 8 days post-infection (0.007 mM dose).
Maintained a near-100% survival rate over the 8-day observation period (0.014 mM dose).
Showed low in vivo toxicity, with survival rates comparable to saline controls.
-
Animal Model:S. aureus 25,923-infected mice wound models (18-22 g, 3-8 weeks of age)[1]
-
Dosage:4× MIC
-
Administration:topical; once daily; 6 days
-
Result:Resulted in a significantly lower residual bacterial load at the wound site compared to PBS and norfloxacin control groups by day 6 post-treatment.
Accelerated wound healing compared to the norfloxacin group, with near-complete wound closure observed by day 6.
Supported normal weight gain throughout the treatment period, consistent with positive control groups.
Chemical Information
-
CAS No. 3031427-16-1
-
분자량 759.16
-
화학식 C34H36ClN4O10PS
-
SMILES
CCOP(OCC)(C(C1=CC(OC)=C(C2=C[N+]3=C(C4=CC5=C(OCO5)C=C4CC3)C=C12)O)NC6=CC=C(C=C6)S(=O)(NC7=NOC(C)=C7)=O)=O.[Cl-]
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antibacterial agent 330 Related Classifications
HY-182027 Related Classifications
Powered by Bioz
Keywords
- Antibacterial agent 330
- 3031427-16-1
- Antibacterial agent330
- Antibacterial agent-330
- Bacterial
- Reactive Oxygen Species (ROS)
- Lactate Dehydrogenase
- DNA/RNA Synthesis
- Gram-negative bacterial strains
- Gram-positive bacterial strains
- methicillin-resistant staphylococcus aureus
- human serum albumin
- lactate dehydrogenase
- staphylococcus aureus 25,923
- Enterococcus faecalis
- bacterial DNA
- sulfamethoxazole-resistant bacterial strains
- reactive oxygen species
- Inhibitor
- inhibitor
- inhibit